Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 2
2012 1
2013 6
2014 2
2015 1
2016 1
2018 1
2019 1
2020 2
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.
Kanada R, Kagoshima Y, Asano M, Suzuki T, Murata T, Haruta M, Takahashi M, Ubukata O, Hashimoto K, Obata K, Kihara K, Kuroha M, Banjo T, Togashi N, Sato K, Yamamoto Y, Suzuki K, Isoyama T, Tominaga Y, Higuchi S, Naito H. Kanada R, et al. Among authors: tominaga y. Bioorg Med Chem Lett. 2022 Jun 15;66:128726. doi: 10.1016/j.bmcl.2022.128726. Epub 2022 Apr 9. Bioorg Med Chem Lett. 2022. PMID: 35413416
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R, Kagoshima Y, Suzuki T, Nakamura A, Funami H, Watanabe J, Asano M, Takahashi M, Ubukata O, Suzuki K, Aikawa T, Sato K, Goto M, Setsu G, Ito K, Kihara K, Kuroha M, Kohno T, Ogiwara H, Isoyama T, Tominaga Y, Higuchi S, Naito H. Kanada R, et al. Among authors: tominaga y. J Med Chem. 2023 Jan 12;66(1):695-715. doi: 10.1021/acs.jmedchem.2c01641. Epub 2022 Dec 26. J Med Chem. 2023. PMID: 36572866
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T. Katayama R, et al. Among authors: tominaga y. Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z. Nat Commun. 2019. PMID: 31399568 Free PMC article.
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Kuki N, Walmsley DL, Kanai K, Takechi S, Yoshida M, Murakami R, Takano K, Tominaga Y, Takahashi M, Ito S, Nakao N, Angove H, Baker LM, Carter E, Dokurno P, Le Strat L, Macias AT, Molyneaux CA, Murray JB, Surgenor AE, Hamada T, Hubbard RE. Kuki N, et al. Among authors: tominaga y. RSC Med Chem. 2023 Oct 19;14(12):2731-2737. doi: 10.1039/d3md00439b. eCollection 2023 Dec 13. RSC Med Chem. 2023. PMID: 38107172
Translational deregulation in PDK-1-/- embryonic stem cells.
Tominaga Y, Tamgüney T, Kolesnichenko M, Bilanges B, Stokoe D. Tominaga Y, et al. Mol Cell Biol. 2005 Oct;25(19):8465-75. doi: 10.1128/MCB.25.19.8465-8475.2005. Mol Cell Biol. 2005. PMID: 16166629 Free PMC article.
20 results